Cargando…

A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients

OBJECTIVES: To compare the efficacy and safety of febuxostat and allopurinol in pyrazinamide (PZA)-induced hyperuricemia in patients taking antitubercular therapy (ATT). METHODS: This randomized controlled study was conducted at a tertiary care teaching institute of Rajasthan in all the sputum-posit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pichholiya, Meenu, Yadav, Arvind Kumar, Luhadia, S. K., Tahashildar, Jameela, Aseri, M. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051245/ https://www.ncbi.nlm.nih.gov/pubmed/27721537 http://dx.doi.org/10.4103/0253-7613.190729

Ejemplares similares

Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients
por: Ziga-Smajic, Nermina, et al.
Publicado: (2020)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
por: Zhang, Fengchun, et al.
Publicado: (2019)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
por: van Leeuwen, Kevin D. B., et al.
Publicado: (2019)

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
por: Mitsuboshi, Satoru, et al.
Publicado: (2015)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
por: MacDonald, Thomas M, et al.
Publicado: (2014)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis”
por: Gao, Linggen, et al.
Publicado: (2022)

Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
por: Park, Seokwoo, et al.
Publicado: (2022)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Comparison of efficacy and safety between febuxostat and allopurinol in early post‐renal transplant recipients with new onset of hyperuricemia
por: Shen, Xiaoju, et al.
Publicado: (2018)

Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice
por: Karve, Ashwini V., et al.
Publicado: (2013)

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
por: Dewi, Christiyanti, et al.
Publicado: (2023)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
por: Bai, Yang, et al.
Publicado: (2023)

Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
por: Kim, Sollip, et al.
Publicado: (2017)

Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy
por: He, Li, et al.
Publicado: (2017)

Allopurinol Effect on Values of Lipid Profile Fractions in Hyperuricemic Patients Diagnosed with Metabolic Syndrome
por: Ziga, Nermina, et al.
Publicado: (2013)

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
por: Rey, Amayelle, et al.
Publicado: (2019)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA
por: Dillon, Nicholas A., et al.
Publicado: (2017)

Effect of febuxostat on blood pressure in hyperuricemic patients: A protocol for a systematic review and meta-analysis
por: Yao, Jia, et al.
Publicado: (2020)

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota
por: Zhao, Zhen Xiong, et al.
Publicado: (2022)

Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis
por: Singh, Jasvinder A., et al.
Publicado: (2018)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study
por: Yu, K-H, et al.
Publicado: (2016)

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A, et al.
Publicado: (2015)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database
por: Altan, Aylin, et al.
Publicado: (2015)

Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin
por: Lehtisalo, Minna, et al.
Publicado: (2020)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Efficacy and safety of febuxostat in elderly female patients
por: Mizuno, Tomohiro, et al.
Publicado: (2014)

Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7bkvfgq4b8r21so9cs6io0lk8l